Efficacy of 24-weekly vs 12-weekly decapeptyl SR treatment in central precocious puberty: a UK multicentre retrospective cohort study
Authors' conclusion
This UK multicenter study provides evidence that 24-weekly Decapeptyl SR is both efficacious and well-tolerated for the management of CPP, with comparable outcomes to the standard 12-weekly regimen.
Study context
- Population
- Children with central precocious puberty treated with gonadotropin-releasing hormone analog (GnRHa), 3 tertiary paediatric endocrinology centres in the UK, September 2008–December 2024164 analysed
- Participants
- 247 children
- Exposure
- 24-weekly vs 12-weekly Decapeptyl SR
- 2 (24 weekly)n = 95
- 1 (12 weekly)n = 69reference
- Outcome
- HPG axis suppression
Methodological detailsmulticentre
- Multicentre
Main finding
As reported in the abstract
- Both regimens achieved effective hypothalamic-pituitary-gonadal (HPG) axis suppression, with no significant differences in LH, FSH or sex steroid concentrations
Observational data: associations, not effects.
Further findings
Clinical outcomes (height velocity, BMI, Tanner staging)
- Comparable between regimens; 24-weekly showed equivalent suppression of pubertal progression
Patient preference
- Among patients who expressed a preference, all favoured the 24-weekly schedule
Original publication
Efficacy of 24-weekly vs 12-weekly decapeptyl SR treatment in central precocious puberty: a UK multicentre retrospective cohort study. J Clin Endocrinol Metab. Published 6 March 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →